ライフサイエンスコーパス: atopic eczema

1 s and low mood have been linked to offspring atopic eczema.

2 and corticosteroids as treatment options for atopic eczema.

3 treatment of some skin conditions including atopic eczema.

4 ) and related to the odds ratio of infantile atopic eczema.

5 standardization of outcome measurements for atopic eczema.

6 crobiota diversity have been associated with atopic eczema.

7 they have a role in alleviating symptoms of atopic eczema.

8 n CYP27A1 was found to be protective against atopic eczema.

9 t less than 4.5 months increased the risk of atopic eczema.

10 month of life was associated with subsequent atopic eczema.

11 ts in adult patients with moderate to severe atopic eczema.

12 suggest that this phototherapy might improve atopic eczema.

13 atecholamine concentrations of patients with atopic eczema.

14 that there is no deficit of linoleic acid in atopic eczema.

15 Atopic eczema (AE) is a challenge for modern medicine, b

16 Atopic eczema (AE) is a chronic inflammatory skin diseas

17 Atopic eczema (AE) is characterized by skin barrier and

18 A characteristic of atopic eczema (AE) is colonization by S. aureus, with ex

19 Undertaking atopic eczema (AE) research using such data is challengi

20 of BMI and GWG on risk of asthma, wheezing, atopic eczema (AE), and hay fever in children during the

21 SE, and LILACS (1945-2016) for the terms AD, atopic eczema (AE), and multiple other eczematous disord

22 t it is unclear whether SIT is effective for atopic eczema (AE).

23 eviews (SRs) on nonallergic comorbidities of atopic eczema (AE).

24 riants are well-established risk factors for atopic eczema (AE).

25 ociated with common skin disorders including atopic eczema (AE)/dermatitis.

26 Atopic eczema affects 1-2% of adults, and can cause cons

27 nst atopic manifestations such as hay fever, atopic eczema, allergic sensitization, or asthma.

28 n = 696) who were later assessed for asthma, atopic eczema and atopy.

29 Allergic rhinitis, atopic eczema and food hypersensitivity were covered in

30 velopmental contribution to the aetiology of atopic eczema and pointing to potentially modifiable inf

31 oducts was related to a reduced incidence of atopic eczema and rhinoconjunctivitis, but no associatio

32 Many research studies have been published on atopic eczema and these are often summarised in systemat

33 Asthma, wheeze, atopic eczema, and allergic rhinitis were measured by us

34 systemic monotherapy for moderate-to-severe atopic eczema, and the therapeutic importance of the thi

35 adjunctive treatment for moderate to severe atopic eczema, and the treatment is well tolerated by mo

36 a significant reduction in the incidence of "atopic eczema," "any positive SPT [skin-prick test]," "s

37 es 6 (n = 2956) and 12 (n = 2872) months and atopic eczema ascertained (based on UK Working Party Cri

38 rd methylation of CpG loci within IL-4R with atopic eczema at 12 months (median ratio 1.02, P = .028)

39 ith a slightly reduced relative risk (RR) of atopic eczema at 6 months (adjusted RR, 0.94; 95% CI, 0.

40 sociated with an increased risk of offspring atopic eczema at age 12 months but not at 6 months, robu

41 sociated with an increased risk of infantile atopic eczema at age 12 months, but no significant assoc

42 ntrations were not associated with offspring atopic eczema at age 6 months.

43 n the UK Southampton Women Survey, infantile atopic eczema at ages 6 and 12 months was ascertained (m

44 plays an important part in the aetiology of atopic eczema, but specific causes are unknown.

45 Atopic eczema decreased between 2008 and 2015.

46 The corresponding figures for atopic eczema/dermatits (AD) were 0.82 (95% CI, 0.68-1.0

47 during the first year of life in relation to atopic eczema development.

48 Asthma, allergic rhinitis, and atopic eczema end points were assessed by using the Inte

49 of azathioprine as systemic monotherapy for atopic eczema has major advantages, which should allow c

50 ne the relation of maternal stress/mood with atopic eczema in the offspring, focusing particularly on

51 amide and related metabolites to the risk of atopic eczema in the offspring.

52 Commonly studied risk factors for atopic eczema included dietary and microbial factors, wh

53 Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease th

54 Atopic dermatitis (AD, also known as atopic eczema) is driven by a complex relationship betwe

55 of eczema (also called atopic dermatitis or atopic eczema) is poorly understood.

56 on-and also a strong genetic risk factor for atopic eczema, marked a significant breakthrough in the

57 Atopic eczema may be a minor inherited abnormality of EF

58 sition may play a role in the development of atopic eczema or atopic sensitization in breastfed infan

59 czema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics

60 HOME is open to anyone with an interest in atopic eczema outcomes research.

61 ational multiprofessional group dedicated to atopic eczema outcomes research.

62 utcome measures and to prioritize topics for atopic eczema outcomes research.

63 02) or respiratory allergies coexistent with atopic eczema (P < .001).

64 Evidence that atopic eczema partly originates in utero is increasing,

65 This mapping of atopic eczema reviews is a valuable resource.

66 ancy and infancy with questionnaire-reported atopic eczema, rhinoconjunctivitis, and asthma in 40,614

67 of probiotic milk products protects against atopic eczema, rhinoconjunctivitis, and asthma in early

68 linking maternal stress at preconception to atopic eczema risk, supporting a developmental contribut

69 y relevant improvement in moderate-to-severe atopic eczema that remains active despite optimum therap

70 2) In one trial outcome, atopic eczema, the intervention had a positive effect on

71 ss and MCID of four outcome measures used in atopic eczema: the Severity Scoring of Atopic Dermatitis

72 ture of trials of calcineurin inhibitors for atopic eczema to document the extent to which comparison

73 response to skin stress in diseases such as atopic eczema, to various agents such as retinoic acid,

74 otal of 174 randomized controlled trials for atopic eczema treatments were identified in which pimecr

75 d inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising e

76 ustry) to determine core outcome domains for atopic eczema trials, to define quality criteria for ato

77 primary or secondary endpoints in all future atopic eczema trials.

78 ife into the core set of outcome domains for atopic eczema trials.

79 Atopic eczema was associated with rs4674343 of CYP27A1 (

80 cant association between post-natal mood and atopic eczema was seen after taking account of preconcep

81 d, milk, and adipose tissue of patients with atopic eczema, whereas concentrations of linoleic acid m